Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial
Purpose: Prospectively scored radiation pneumonitis (RP) observed in a national, randomized phase II dose-escalation trial for patients with locally advanced non-small cell lung cancer (NSCLC) was investigated. Methods: Patients with stage IIB-IIIB histologically proven NSCLC were treated with conco...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-03-01
|
Series: | Clinical and Translational Radiation Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630820301002 |
id |
doaj-c71c88fe9d9047ac84a6c37ef1fc226b |
---|---|
record_format |
Article |
spelling |
doaj-c71c88fe9d9047ac84a6c37ef1fc226b2021-06-02T21:02:03ZengElsevierClinical and Translational Radiation Oncology2405-63082021-03-0127814Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trialChristina M. Lutz0Marianne M. Knap1Lone Hoffmann2Ditte S. Møller3Olfred Hansen4Carsten Brink5Tine Schytte6Christa H. Nyhus7Tine McCulloch8Svetlana Borissova9Markus Alber10Azza A. Khalil11Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Corresponding author at: Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.Department of Oncology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Vejle Hospital, Vejle, DenmarkDepartment of Oncology, Aalborg Hospital, Aalborg, DenmarkDepartment of Oncology, Herlev Hospital, Herlev, DenmarkHeidelberg Institute for Radiation Oncology, Heidelberg University Hospital, Heidelberg, GermanyDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkPurpose: Prospectively scored radiation pneumonitis (RP) observed in a national, randomized phase II dose-escalation trial for patients with locally advanced non-small cell lung cancer (NSCLC) was investigated. Methods: Patients with stage IIB-IIIB histologically proven NSCLC were treated with concomitant chemo-radiotherapy (oral Vinorelbine 3times/week) at 60 Gy/30fx (A–59pts) and 66 Gy/33fx (B–58pts) from 2009 to 2013 at five Danish RT centers. Grade 2 RP (CTCAEv3.0) was investigated with univariate analysis for association with clinical and dosimetric parameters, including dyspnea and cough at baseline and during RT. Multivariable logistic regression and Cox regression with regularization were used to find a multivariable model for RP ≥ G2. Results: Despite a tendency of higher mean lung dose in the high-dose arm (median[range] A = 14.9 Gy[5.8,23.1], B = 17.5 Gy[8.6,24.8], p = 0.075), pulmonary toxicities were not significantly different (RP ≥ G2 41%(A) and 52%(B), p = 0.231). A Kaplan Meier analysis of the time to RP ≥ G2 between the two arms did not reach statistical significance (p = 0.180). Statistically significant risk factors for RP ≥ G2 were GTV size (OR = 2.091/100 cm3, p = 0.002), infection at baseline or during RT (OR = 8.087, p = 0.026), dyspnea at baseline (OR = 2.184, p = 0.044) and increase of cough during RT (OR = 2.787, p = 0.008). In the multivariable logistic regression and the Cox regression analysis, the deviances of the most predictive models were within one standard deviation of the null model. Conclusion: No statistical difference between the high- and low dose arm was found in the risk of developing RP. The univariate analysis identified target volume, infection, dyspnea at baseline, and increase of cough during RT as risk factors for RP. The number of patients was too small to establish a statistically sound multivariable model.http://www.sciencedirect.com/science/article/pii/S2405630820301002ProspectiveRadiation pneumonitisLocally-advanced non-small cell lung cancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christina M. Lutz Marianne M. Knap Lone Hoffmann Ditte S. Møller Olfred Hansen Carsten Brink Tine Schytte Christa H. Nyhus Tine McCulloch Svetlana Borissova Markus Alber Azza A. Khalil |
spellingShingle |
Christina M. Lutz Marianne M. Knap Lone Hoffmann Ditte S. Møller Olfred Hansen Carsten Brink Tine Schytte Christa H. Nyhus Tine McCulloch Svetlana Borissova Markus Alber Azza A. Khalil Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial Clinical and Translational Radiation Oncology Prospective Radiation pneumonitis Locally-advanced non-small cell lung cancer |
author_facet |
Christina M. Lutz Marianne M. Knap Lone Hoffmann Ditte S. Møller Olfred Hansen Carsten Brink Tine Schytte Christa H. Nyhus Tine McCulloch Svetlana Borissova Markus Alber Azza A. Khalil |
author_sort |
Christina M. Lutz |
title |
Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial |
title_short |
Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial |
title_full |
Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial |
title_fullStr |
Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial |
title_full_unstemmed |
Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial |
title_sort |
prospectively scored pulmonary toxicities in non-small cell lung cancer: results from a randomized phase ii dose escalation trial |
publisher |
Elsevier |
series |
Clinical and Translational Radiation Oncology |
issn |
2405-6308 |
publishDate |
2021-03-01 |
description |
Purpose: Prospectively scored radiation pneumonitis (RP) observed in a national, randomized phase II dose-escalation trial for patients with locally advanced non-small cell lung cancer (NSCLC) was investigated. Methods: Patients with stage IIB-IIIB histologically proven NSCLC were treated with concomitant chemo-radiotherapy (oral Vinorelbine 3times/week) at 60 Gy/30fx (A–59pts) and 66 Gy/33fx (B–58pts) from 2009 to 2013 at five Danish RT centers. Grade 2 RP (CTCAEv3.0) was investigated with univariate analysis for association with clinical and dosimetric parameters, including dyspnea and cough at baseline and during RT. Multivariable logistic regression and Cox regression with regularization were used to find a multivariable model for RP ≥ G2. Results: Despite a tendency of higher mean lung dose in the high-dose arm (median[range] A = 14.9 Gy[5.8,23.1], B = 17.5 Gy[8.6,24.8], p = 0.075), pulmonary toxicities were not significantly different (RP ≥ G2 41%(A) and 52%(B), p = 0.231). A Kaplan Meier analysis of the time to RP ≥ G2 between the two arms did not reach statistical significance (p = 0.180). Statistically significant risk factors for RP ≥ G2 were GTV size (OR = 2.091/100 cm3, p = 0.002), infection at baseline or during RT (OR = 8.087, p = 0.026), dyspnea at baseline (OR = 2.184, p = 0.044) and increase of cough during RT (OR = 2.787, p = 0.008). In the multivariable logistic regression and the Cox regression analysis, the deviances of the most predictive models were within one standard deviation of the null model. Conclusion: No statistical difference between the high- and low dose arm was found in the risk of developing RP. The univariate analysis identified target volume, infection, dyspnea at baseline, and increase of cough during RT as risk factors for RP. The number of patients was too small to establish a statistically sound multivariable model. |
topic |
Prospective Radiation pneumonitis Locally-advanced non-small cell lung cancer |
url |
http://www.sciencedirect.com/science/article/pii/S2405630820301002 |
work_keys_str_mv |
AT christinamlutz prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT mariannemknap prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT lonehoffmann prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT dittesmøller prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT olfredhansen prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT carstenbrink prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT tineschytte prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT christahnyhus prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT tinemcculloch prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT svetlanaborissova prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT markusalber prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial AT azzaakhalil prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial |
_version_ |
1721400980972503040 |